Bevacizumab and AZD2171 in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Bevacizumab and AZD2171 in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

This study is currently recruiting participants.

Study NCT00458731 Information provided by National Cancer Institute (NCI)

First Received: April 9, 2007 Last Updated: June 27, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Lymphoma
Small Intestine Cancer

Additional conditions recognized in this trial

Astrocytoma
Central Nervous System Neoplasms
Duodenal Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
Nervous System Neoplasms

Interventions listed in this trial

bevacizumab
cediranib maleate
flow cytometry
fluorescent antibody technique
laboratory biomarker analysis
pharmacological study
biopsy

More general drug interventions related to this trial

Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

Sponsors listed in this trial

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Back to top of Main Content